BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...

Pharma trading halted, news pendingDon't Miss our Black Friday Offers:Unlock your investing potential with TipRanks ...

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look ...

In a report released yesterday, Anupam Rama from J.P. Morgan maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price ...

Bullish option flow detected in BridgeBio (BBIO) Pharma with 2,983 calls trading, 1.0x expected, and implied vol increasing over 2 points to 132.22%. Dec-24 30 calls and Dec-24 35 calls are the most ...

Equities researchers at Cantor Fitzgerald decreased their FY2024 earnings estimates for BridgeBio Pharma in a report released ...

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have been assigned an average recommendation of “Moderate ...

On Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) presented initial outcomes from the ATTRibute-CM open-label extension (OLE) ...

In a report released today, Greg Harrison from Scotiabank maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on BBIO stock, giving a Buy rating on November 15.Don't Miss our ...

One thing we could say about the analysts on BridgeBio Pharma, Inc. ( NASDAQ:BBIO) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the ...

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price upped by Scotiabank from $44.00 to $45.00 in a research note published on Friday,Benzinga reports. The brokerage currently has a ...